Journal of Clinical Endocrinology & Metabolism, Vol 80, 3421-3424, Copyright © 1995 by Endocrine Society

ARTICLES

The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland

S Matsubayashi, K Kawai, Y Matsumoto, T Mukuta, T Morita, K Hirai, F Matsuzuka, K Kakudoh, K Kuma and H Tamai
Department of Psychosomatic Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

Ninety-five patients with papillary thyroid carcinoma (PTC) who received primary surgical treatment in 1983 at Kuma Hospital and were followed until 1992 were the subjects of this study. Initial therapy was tumor resection for 5 patients, lobectomy for 23 patients, total thyroidectomy with unilateral modified neck dissection for 60 patients, and total thyroidectomy with bilateral modified neck dissection for 7 patients. Clinical stage at diagnosis was as follows. Class I included 28 patients with intrathyroidal disease, class II included 60 patients with positive cervical lymph nodes, and class II included 7 patients with tumor invasion into tissue outside of the thyroid gland. Recurrence of the tumor was evaluated according to lymphocytic infiltration in the thyroid gland. Group A consisted of 36 patients with PTC associated with lymphocytic infiltration, 26 with infiltration surrounding the tumor, 3 with infiltration inside of the tumor, and 7 with both. Group B consisted of the remaining 59 patients with PTC with no lymphocytic infiltration. There were no differences in age, sex, initial tumor size, or initial treatment between groups A and B. Antithyroglobulin antibody and/or antimicrosomal antibody were positive in 16 patients from group A and 4 patients from group B (P < 0.001). Class I included 14 patients from each group, class II included 22 patients from group A and 38 patients from group B, and class III included 7 patients, all from group B. Recurrence of the tumor was found in only 1 group A patient (2.8%), but in 11 patients of group B (18.6%). The percentage of patients free from recurrence over the 10 yr of follow-up in group A was significantly higher than that in group B (by Cox-Mantel test, P < 0.01). The time between initial treatment and recurrence was 2-10 yr. In comparing the clinical stage at the time of initial treatment, recurrence was found in 1 class II patient from group A (4.5%) and in 1 class I (7.1%), 6 class II (15.8%), and 4 class III (57.1%) patients from group B. No patients died during the 10 yr of follow-up. In conclusion, 1) lymphocytic infiltration surrounding the tumor or inside the tumor in PTC might be of use as a means for predicting a favorable prognosis; and 2) class II or class III patients with no lymphocytic infiltration had a high rate of recurrence.

This article has been cited by other articles:

				C. S. Mitsiades, V. Poulaki, G. Fanourakis, E. Sozopoulos, D. McMillin, Z. Wen, G. Voutsinas, S. Tseleni-Balafouta, and N. Mitsiades Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin. Cancer Res., June 15, 2006; 12(12): 3705 - 3712. [Abstract] [Full Text] [PDF]

				E. Roti, R. Rossi, G. Trasforini, F. Bertelli, M. R. Ambrosio, L. Busutti, E. N. Pearce, L. E. Braverman, and E. C. degli Uberti Clinical and Histological Characteristics of Papillary Thyroid Microcarcinoma: Results of a Retrospective Study in 243 Patients J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2171 - 2178. [Abstract] [Full Text] [PDF]

				B Jarzab, D Handkiewicz-Junak, and J Wloch Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review Endocr. Relat. Cancer, December 1, 2005; 12(4): 773 - 803. [Abstract] [Full Text] [PDF]

				J. Modi, A. Patel, R. Terrell, R. M. Tuttle, and G. L. Francis Papillary Thyroid Carcinomas from Young Adults and Children Contain a Mixture of Lymphocytes J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4418 - 4425. [Abstract] [Full Text] [PDF]

				E. N. Pearce, A. P. Farwell, and L. E. Braverman Thyroiditis N. Engl. J. Med., June 26, 2003; 348(26): 2646 - 2655. [Full Text] [PDF]

				D. J. Powell Jr., L. C. Eisenlohr, and J. L. Rothstein A Thyroid Tumor-Specific Antigen Formed by the Fusion of Two Self Proteins J. Immunol., January 15, 2003; 170(2): 861 - 869. [Abstract] [Full Text] [PDF]

				S. Gupta, A. Patel, A. Folstad, C. Fenton, C. A. Dinauer, R. M. Tuttle, R. Conran, and G. L. Francis Infiltration of Differentiated Thyroid Carcinoma by Proliferating Lymphocytes Is Associated with Improved Disease-Free Survival for Children and Young Adults J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1346 - 1354. [Abstract] [Full Text]

				N. Mitsiades, V. Poulaki, S. Tseleni-Balafouta, D. A. Koutras, and I. Stamenkovic Thyroid Carcinoma Cells Are Resistant to FAS-mediated Apoptosis But Sensitive to Tumor Necrosis Factor-related Apoptosis-inducing Ligand Cancer Res., August 1, 2000; 60(15): 4122 - 4129. [Abstract] [Full Text]

				P. L. Arscott, T. Stokes, A. Myc, T. J. Giordano, N. W. Thompson, and J. R. Baker Jr. Fas (CD95) Expression is Up-Regulated on Papillary Thyroid Carcinoma J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4246 - 4252. [Abstract] [Full Text]

				J. D. Bretz, M. Rymaszewski, P. L. Arscott, A. Myc, K. B. Ain, N. W. Thompson, and J. R. Baker Jr. TRAIL Death Pathway Expression and Induction in Thyroid Follicular Cells J. Biol. Chem., August 13, 1999; 274(33): 23627 - 23632. [Abstract] [Full Text] [PDF]

				N. Mitsiades, V. Poulaki, G. Mastorakos, S. Tseleni-Balafouta, V. Kotoula, D. A. Koutras, and M. Tsokos Fas Ligand Expression in Thyroid Carcinomas: A Potential Mechanism of Immune Evasion J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2924 - 2932. [Abstract] [Full Text]

				K.-C. Loh, F. S. Greenspan, F. Dong, T. R. Miller, and P. P. B. Yeo Influence of Lymphocytic Thyroiditis on the Prognostic Outcome of Patients with Papillary Thyroid Carcinoma J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 458 - 463. [Abstract] [Full Text]

				C. A. Spencer, M. Takeuchi, M. Kazarosyan, C. C. Wang, R. B. Guttler, P. A. Singer, S. Fatemi, J. S. LoPresti, and J. T. Nicoloff Serum Thyroglobulin Autoantibodies: Prevalence, Influence on Serum Thyroglobulin Measurement, and Prognostic Significance in Patients with Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1121 - 1127. [Abstract] [Full Text]

				K. Kawai, E. Resetkova, T. Enomoto, V. Fornasier, and R. Volpé Is Human Leukocyte Antigen-DR and Intercellular Adhesion Molecule-1 Expression on Human Thyrocytes Constitutive in Papillary Thyroid Cancer? Comparative Studies of Human Thyroid Xenografts in Severe Combined Immunodeficient and Nude Mice J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 157 - 164. [Abstract] [Full Text]

				A. Fiumara, A. Belfiore, G. Russo, E. Salomone, G. M. Santonocito, O. Ippolito, R. Vigneri, and P. Gangemi In Situ Evidence of Neoplastic Cell Phagocytosis by Macrophages in Papillary Thyroid Cancer J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1615 - 1620. [Abstract] [Full Text] [PDF]